The overall use of heparin in these patients was also suggested by the management document from the World Health Organization.13 Although this protocol implementation was used for the last 5 patients, and the conclusions might not be generalizable, we did not observe any new thrombotic complications. In addition, none of these 5 patients died. The potential beneficial effect of heparin in our COVID-19 surgical patients might find some support in experimental data. First, plenty of data have shown that heparin is the most effective method for the prevention of thromboembolism.14 Second, it is well-known that heparin has suppressive activity against the development of a cytokines storm, which is a typical pathogenetic process of COVID-19 infection that eventually results in acute lung injury and death.15 , 16 Finally, it has already been shown that heparin has competitive binding activity to the coronavirus. This final aspect might result in a significant reduction of the pathogen's activity, which would bind to the heparin, instead of attacking the cells of the organism by inhibiting cell penetration.17, 18, 19, 20